research use only

Abrocitinib (PF-04965842) JAK inhibitor

Name: Abrocitinib (PF-04965842)
Brand: Selleck Chemicals
SKU: S8765
Availability: InStock
Rating: 5 (10 reviews)

Cat.No.S8765

Abrocitinib (PF-04965842) is a potent JAK1 inhibitor, with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.

Abrocitinib (PF-04965842) JAK inhibitor Chemical Structure

Quality Control

Batch: S876501 DMSO]65 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.45%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.45

Related Targets	EGFR STAT Pim
Other JAK Inhibitors	BMS-986165 (Deucravacitinib) AZD1480 WP1066 Filgotinib (GLPG0634) Momelotinib (CYT387) AT9283 Gandotinib (LY2784544) Pacritinib (SB1518) NVP-BSK805 2HCl TG101209

Solubility

In vitro
Batch:

DMSO : 65 mg/mL (200.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.250mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 65 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	323.41	Formula	C₁₄H₂₁N₅O₂S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1622902-68-4	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	JAK1 (Cell-free assay) 29 nM JAK2 (Cell-free assay) 803 nM TYK2 (Cell-free assay) 1.253 μM
In vitro	Abrocitinib (PF-04965842) is a potent JAK inhibitor with IC50 of 29 and 803 nM for JAK1 and JAK2, respectively.
In vivo	Abrocitinib (PF-04965842) was examined for its physicochemical properties and pharmacokinetic parameters in rats following doses of 1 mg/kg iv or 3 mg/kg po. Its clearance is low relative to total liver blood flow (CL = 26.6 mL/min/kg). Vdss = 1.04 L/kg. T_1/2 = 1.1 h. The oral availability of this compound is 95.6%. It demonstrates efficacy in a dose-responsive manner in a therapeutic rat adjuvant-induced arthritis model.
References	[1] https://pubmed.ncbi.nlm.nih.gov/29298069/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-04)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06807281	RECRUITING	Atopic Dermatitis	Pfizer	2025-12-02	PHASE3
NCT07352566	NOT_YET_RECRUITING	Psoriasis; Atopic Dermatitis	University of California, San Francisco	2026-08-01	PHASE4
NCT06807268	RECRUITING	Eczema	Pfizer	2025-07-24	PHASE3
NCT07242638	RECRUITING	Atopic Dermatitis; Alopecia Areata	Icahn School of Medicine at Mount Sinai	2026-01-12	PHASE2
NCT05743244	ACTIVE_NOT_RECRUITING	Diabetes Mellitus, Type 1	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2023-10-19	PHASE2
NCT06119490	RECRUITING	Toxic Epidermal Necrolysis	Peng Zhang	2023-07-05	EARLY_PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):